

10/02/97

226/213
PATENT

A/Noje

Box PATENT APPLICATION
Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of:

Inventor(s) : CHUN-MING CHEN, CHARLES R. CARPENTER, HAOYI GU, and ALI NAQUI

For: METHOD & APPARATUS FOR CONCURRENTLY DETECTING PATHOGENIC ORGANISMS AND ANTIMICROBIAL SUSCEPTIBILITY

Enclosed are:

37 page(s) specification; 6 page(s) claims;
 1 page(s) abstract.

sheets of drawings (informal formal).

Combined Declaration and Power of Attorney (signed unsigned) (2 pages).

Assignment of the invention to:

Certified copy(s) of priority documents ().

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231.

EM104356625US
Express Mail mailing no.

Monty Srioudom
name of person mailing paper

date of deposit

Monty Srioudom
signature of person mailing paper

____ A Verified Statement Claiming Small Entity Status under
37 CFR §1.9 and §1.27.

____ Sequence Listing, Disk and Statement.

The filing fee has been calculated as shown below:

-Total Claims	<u>19</u>	(-20)	<u> </u>	x (\$22)	\$ 0.00
-Independent Claims	<u> 3</u>	(-3)	<u> </u>	x (\$82)	\$ 0.00
-Multiple Dependent Claim(s)				(\$270)	\$
-Statutory Basic Filing Fee				(\$790)	\$ 790.00
-Surcharge 37 CFR 1.16(e)				(\$130)	\$
TOTAL OF ABOVE CALCULATIONS					\$ 790.00
-Reduction for Small Entity (½)					\$ 395.00
-Assignment				(\$40)	\$
TOTAL FEES SUBMITTED HEREWITH					\$ N/A

X This application is filed without fee or signed
declaration pursuant to 37 CFR §1.53.

____ A check in the amount of \$_____ to cover the above
fees is enclosed.

The Commissioner is hereby authorized to charge payment of the fees associated with this communication, or credit any overpayment, to Deposit Account 12-2475. A duplicate copy of this sheet is enclosed.

Respectfully Submitted
LYON & LYON

Dated: 1 October 1997


Timothy J. Lithgow
Reg. No. 36,856

Lyon & Lyon, LLC
First Interstate World Center
633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(619) 552-8400

METHOD AND APPARATUS FOR CONCURRENTLY DETECTING PATHOGENIC
ORGANISMS AND ANTIMICROBIAL SUSCEPTIBILITY

FIELD OF THE INVENTION

5 This invention relates to the field of chemistry, biology, and microbiology. In particular, it relates to a microbiological test method, compositions and apparatus, and especially to microbial detection of the majority of gram negative urinary pathogens and to determining the antibiotic 10 susceptibility of the urinary pathogens obtained directly from a urine sample.

BACKGROUND ART

20 Bacterial urinary tract infections are common human and veterinary diseases. The enteric gram negative bacilli normally reside in the intestinal tract and become pathogens when found in the urinary tract; these enteric bacilli are classified in the family of *Enterobacteriaceae*. The primary causative agents of urinary tract infections are gram negative bacilli. Typically, these include *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, and *Proteus mirabilis*, etc. Infrequently, gram positive cocci (such as, *Staphylococcus aureus* and *Enterococcus faecalis*) and other gram negative bacteria (such as, *Pseudomonas aeruginosa*) may 25 be urinary pathogens. Other gram positive cocci (*Staphylococcus*, *Streptococcus*) and gram positive bacilli (diphtheroids, *Bacillus subtilis*) are most frequently encountered as normal urethral contaminants.

30 Bacteriologic testing is commonly performed on patients experiencing symptoms consistent with urinary tract infections. Microorganisms isolated from patients (human and

veterinary) are tested to determine the identity of the pathogens and their susceptibility to antibiotics. Information pertaining to minimum inhibitory concentrations (MIC) or the categorical interpretations (susceptible, moderate susceptible, intermediate resistant, or resistant) of antimicrobial agents against an identified pathogen are critical for a (medical or veterinary) practitioner to confirm or select a proper treatment regime for urinary tract infections.

The clinical effectiveness of antimicrobial chemotherapy for bacterial urinary tract infections requires the correct identification of the causing pathogens and the selection of an appropriate antibiotic treatment regime to eradicate the disease-causing bacteria. The suspect pathogens are isolated by inoculating the specimen onto a culture medium, which is then incubated at 35°C for 24-48 hours to obtain bacterial growth. The bacterial identity and its antimicrobial susceptibility are then determined by a series of subsequent biochemical tests and standard antimicrobial susceptibility tests.

Methods for routine antimicrobial susceptibility determination of the identified pathogens include the broth dilution method and the agar diffusion assay. The broth dilution method involves the inoculation of a standardized microbiological inoculum (e.g., 1-5 X 10⁵ cfu/ml) of the pure bacterial isolate in question into a growth medium (typically, a cation-adjusted Mueller Hinton broth) containing a series of predetermined concentrations of a given antibiotic whose MIC is sought to be determined. The inoculated medium is incubated for 18-24 hours and observed for visible growth. The lowest antibiotic concentration that

completely inhibits visible growth of the isolated organism as detected by the unaided eye is recorded as the MIC.

5 The agar diffusion method involves the placement of an antibiotic containing disc or an antibiotic gradient strip on the surface of an agar medium (typically Mueller Hinton agar plate) that has been inoculated with the pure isolate of the microorganism in question. The antibiotic substance then diffuses away from the disc such that the effective concentration of antibiotic varies as a function of the 10 radius from the disc or strip. Thus, the diameter of a resulting no growth area about the disc should be proportional to the MIC.

20 Procedures to obtain these antibiotic susceptibility data are often time-consuming (48-72 hours), cumbersome, require highly skilled personnel, or require expensive, automatic equipment. Patients with symptoms of a urinary tract infection (in particular, feline and canine) are often treated without regard to bacteriologic finding because of time delays and cumbersome assay procedures required by conventional culture methods. This may compromise the quality of patient care and contribute to the emerging antibiotic resistant bacteria due to the improper use of antibiotics.

25 Thus, there is a need for improved microbiologic tests and antibiotic susceptibility tests, related materials, and related assay devices. If the test procedures could be simplified so that no highly skilled personnel were required for performing the test, and test results were obtained in a shorter period of time, it would facilitate the ability of 30 health care practitioners to confirm or select a proper treatment regime for urinary tract infections. Earlier

receipt by health care practitioners (medical or veterinary) of accurate antimicrobial susceptibility information would result in better patient care, and prevent the emerging of antibiotic resistant bacteria due to the improper use of antibiotics.

Furthermore, the use of chromogenic or fluorogenic enzyme substrates have been widely used in a varieties of microbial diagnostic applications. Edberg (U.S. patent No. 4,925,789) described a medium containing a nutrient indicator which, when metabolized by target bacteria, releases a moiety which imparts a color or other detectable change to the medium. Chen and Gu (U.S. patent 5,620,865) used a fluorogenic compound, 4-methylumbelliferyl- β -D-glucopyranoside, in a micro-specific medium for detecting enterococci. Townsend and Chen (U.S. Application No. 08/484,593, filed June 7, 1995) described the use of fluorogenic enzyme substrates cocktail to detect bacterial contamination in food products. Koumura et al. (U.S. patent No. 4,591,554) describes the use of 4-methylumbelliferyl derivatives fluorogenic analysis to detect and determine the number of microorganisms based on the amount of liberated umbelliferone derivatives. Perry and Miller used an umbelliferyl-conjugated N-acetyl- β -D-galctosaminide for specific identification of a pathogenic yeast, *Candida albicans*, (J. Clin. Micro. (1987) 25:2424-2425).

The traditional endpoint of antimicrobial susceptibility determination involves the direct visual or instrument recognition of microbial growth in either a biological matrix, e.g., broth or agar. Urban and Jarstrand used a nitroblue tetrazolium dye to determine the susceptibility of bacteria to antibiotics (J. Antimicro. Chem. (1981) 8:363-

369). The SENSITITRE™ system uses an instrument capable of automatically reading antimicrobial susceptibility microdilution trays (J. Clin. Microbiol. (1985) 22:187-191). In this procedure, microbial growth and MIC are determined by the measurement of fluorescence produced by bacterial enzyme action on fluorescence substrates. It is disclosed that fluorogenic substrates for this group of bacteria are selected from 7-(N)-(aminoacyl)-7-amido-4-methylcoumarin, 4-methylumbelliferyl noanate, 4-methylumbelliferyl phosphate. Badal et al. (U.S. Patent No: 5,457,030) disclosed the use of a mixture of fluorogenic substrates consisting of leucine-7-amido-4-methylcoumarin, phenylalanine-7-amido-4-methylcoumarin, and 4-methylumbelliferyl phosphate and a predetermined amount of an antimicrobial agent to form a mixture to determine the antimicrobial susceptibility of the majority of clinically significant gram positive organisms.

All these prior art approaches involve the use of a clone of a bacterial isolate obtained from clinical specimen prior to identification and antimicrobial susceptibility tests. Colonies, i.e., clones, of bacterial cultures, when prepared from the biological specimen, are harvested after a sufficient period of growth. The harvested colony is suspended in a suitable aqueous liquid for biochemical identification and antimicrobial susceptibility test.

Although 90-95% of all urinary infections are caused by a single type of organism, contaminating normal flora are often present on the patient's skin or in the environment, and these organisms can provide an arbitrary contaminant to a urinary sample. Contaminating microflora in a urine specimen are particularly prevalent in veterinary practices relative to medical practice in humans; this is because the specimen

collection in veterinary practices tends to be more difficult to control with animals. In general, feline and canine urine specimens may be obtained through a number of means including cystocentesis, catheterization, manual compression of the urinary bladder and natural micturition. Cystocentesis is least likely to introduce microscopic contaminants (including microbial contamination). If the samples are collected by manual compression of bladder or natural micturition, even with the effort of collecting "mid-stream" sample, microbial contamination in the sample is expected. Although cystocentesis is recommended, other methods are often used in veterinarian practices due to the difficulty in controlling animals. Problems with the contamination of urine specimens have, in the past, prevented accurate assessments of effective antibacterial therapies for urinary tract infections. Accordingly, devices and related methods are needed which distinguish uropathogens from contaminating organisms.

DISCLOSURE OF THE INVENTION

Disclosed is a multicompartiment assay device comprising: at least one compartment comprising a viable organism control medium capable of sustaining growth of total microbial organisms; at least one compartment comprising a medium capable of selectively sustaining growth of target microbial organisms; and, at least one compartment comprising an antimicrobial susceptibility interpretation medium. The medium capable of sustaining growth of total microbial organisms can comprise a means for detection of total microbial organisms; the means for detection can comprise an enzyme substrate comprising a detectable moiety capable of

being released from the substrate by action of a microbial enzyme. The medium capable of sustaining growth of target microbial organisms can comprise a means for detection of target microbial organisms; the means for detection of target microbial organisms can comprise an enzyme substrate comprising a detectable moiety capable of being released from the substrate by action of a microbial enzyme. The antimicrobial susceptibility interpretation medium can comprise a means for detection of microbial organisms which have grown or reproduced in the susceptibility interpretation medium; the means for detection can comprise an enzyme substrate comprising a detectable moiety capable of being released from the substrate by action of a microbial enzyme. The medium capable of sustaining growth of total microbial organisms, the medium capable of sustaining growth of target microbial organisms, and, the antimicrobial susceptibility interpretation medium each comprise a means for producing an identical type of detectable signal. The antimicrobial susceptibility interpretation medium can comprise amoxicillin, clavulanic acid/amoxicillin, or, enrofloxacin.

Disclosed is a method of detecting the presence of target microbial microorganisms in a biological sample and of simultaneously determining the susceptibility of such microorganisms to antimicrobial agents, said method comprising steps of: providing a multicompartment assay device comprising at least one compartment comprising a medium capable of sustaining growth of total microbial organisms, at least one compartment comprising a medium capable of sustaining growth of target microbial organisms; and, at least one compartment comprising an antimicrobial susceptibility interpretation medium; placing a portion of

the biological sample respectively in said at least one compartment comprising a medium capable of sustaining growth of total microbial organisms; said at least one compartment comprising a medium capable of sustaining growth of target microbial organisms; and, said at least one compartment comprising an antimicrobial susceptibility interpretation medium comprising an antimicrobial agent; whereby growth of organisms in said at least one compartment comprising a medium capable of sustaining growth of total microbial organisms indicates the presence of bacteria in the sample; growth of organisms in said at least one compartment comprising a medium capable of sustaining growth of target microbial organisms indicates the presence of target microbial organisms in the sample, and growth of organisms in said at least one compartment comprising an antimicrobial susceptibility interpretation medium indicates that the organisms lack susceptibility to that antimicrobial agent. The biological fluid can be urine, blood, saliva, cerebrospinal fluid, fluid from a wound, a chemical sample, or an environmental sample. The target microbial microorganisms can be uropathogens, such as *Enterobacteriaceae*; or, *Escherichia coli*, *Klebsiella spp.*, *Enterobacter spp.*, *Proteus mirabilis* *Proteus vulgaris*, *Morganella morganii*, *Providencia rettgeri*, *Acinetobacter spp.*, *Staphylococcus aureus*, *Enterococcus faecalis*, or *Streptococci*.

The step of providing a device comprising the at least one antimicrobial susceptibility interpretation medium can provide an antimicrobial susceptibility interpretation medium comprising amoxicillin, clavulanic acid/amoxicillin, or, enrofloxacin.

Disclosed is a multicompartiment assay device comprising: a compartment comprising a medium capable of sustaining growth of total bacterial organisms; a compartment comprising a medium capable of sustaining growth of target uropathogenic bacteria; a compartment comprising an antimicrobial susceptibility interpretation medium comprising amoxicillin; a compartment comprising an antimicrobial susceptibility interpretation medium comprising amoxicillin and clavulanic acid; and, a compartment comprising an antimicrobial susceptibility interpretation medium comprising enrofloxacin.

MODES FOR CARRYING OUT INVENTION

DEFINITIONS

The term "microbe" or "microbial organism" is intended any organism capable of being present in a biological sample. Such organisms include but are not limited to bacteria and fungi. Preferred embodiments of the invention detect bacterial microbes in a biological sample.

By "Enterobacteriaceae" is meant the groups of gram negative rods, motile by perichichous flagella or nonmotile, which do not form endospores or microcysts, and, are not acid-fast. These group of bacteria can grow in the presence or absence of oxygen, use D-glucose as sole carbon source, and produce acid and visible gas. These include but are not limited to, the following genera of microorganisms: *Escherichia*, *Shigella*, *Klebsiella*, *Enterobacter*, *Citrobacter*, *Proteus*, *Salmonella*, *Providencia*, *Morganella*, *Yersinia*, *Erwinia*, and *Hafnia*. These bacteria include those described

-10-

or referred to in "Bergey's Manual of Systematic Bacteriology" (1989) (Williams and Wilkins, U.S.A.).

By "urinary pathogen" or "uropathogen" is meant bacteria that cause the human and veterinary urinary tract infections. Such bacteria include, but are not limited to, the group of enteric gram negative bacilli (*Enterobacteriaceae*) which normally reside in the intestinal tract, which when found in the urinary tract often produce clinical symptoms of urinary tract infection. Examples of these bacteria include but are not limited to, the enteric gram negative bacteria (such as *Escherichia coli*, *Klebsiella* spp., *Enterobacter* spp., *Proteus mirabilis*, *Proteus vulgaris*, *Morganella morganii*, *Providencia rettgeri*, and *Acinetobacter* spp.). Infrequently, *Pseudomonas* spp. and certain gram positive cocci (*Staphylococcus aureus*, *Enterococcus faecalis*, and *Streptococci*) may be urinary pathogens. These terms are not meant to exclude genera that have yet to be discovered but may later be identified and included in this group of bacteria by those skill in the art.

By a "primary gram negative urinary pathogens" is meant the group of bacteria which cause at least 85-90% of the human and veterinary urinary tract infections. These include but are not limited to: *Escherichia coli*, *Klebsiella* spp., *Enterobacter* spp., and *Proteus mirabilis*. This term is not meant to exclude genera that have yet to be discovered but may later be identified and included in this group of bacteria by those skill in the art.

By the term "target microbe" or "target microbial organism" means the microorganism whose presence or absence is sought to be detected. For example, it includes any species of the primary urinary pathogens or any microbe suspected of being present in a given biological sample.

By the term "viable organism control medium" means a medium which allows growth of total microbial organisms present in a test sample. For example, if fungi are detected, this medium is referred to as a "total viable fungi medium" or "TVF" medium, and is not selective for particular fungal species. If bacteria are detected, the media is referred to as "total viable bacteria medium" or "TVB medium", and includes any media which can support bacterial growth in a test sample, and is not selective for particular bacterial species; examples include but are not limited to, trypticase soy broth, nutrient broth, etc., as appreciated by one of ordinary skill in the art. In preferred embodiments, a "viable organism control medium" detects bacterial growth by providing the ability to identify bacterial enzymes (e.g., phosphatase, β -glucosidase, and L-alanine aminopeptidase) from diverse microbial species. In a preferred embodiment, the viable organism control medium is a medium described in the U.S. Application No. 08/484,593, filed June 7, 1995 in the names of Townsend and Chen, entitled, "Method and Composition for Detecting Bacterial Contamination in Food Products". In preferred embodiments, this term includes media which contain one or more enzyme substrates. The bacterial enzymes are identified because they liberate fluorescent moieties that exhibit detectable signals with identical emission wavelengths. This medium takes advantage of combining different bacterial enzyme activities from diverse microbes, to create a broader enzyme activity spectrum; the broadened spectrum enables the detection of total bacteria in a test sample. The microorganisms detected by this medium include but are not limited to the gram negative urinary pathogens (e.g., *Escherichia coli*,

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1098

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

1450

1455

1460

1465

1470

1475

1480

1485

1490

1495

1500

1505

1510

1515

1520

1525

1530

1535

1540

1545

1550

1555

1560

1565

1570

1575

1580

1585

1590

1595

1600

1605

1610

1615

1620

1625

-12-

Klebsiella spp., *Enterobacter* spp., *Proteus mirabilis*, *Pseudomonas aeruginosa* etc.), the gram positive pathogens (*Staphylococcus aureus*, *Enterococci*, etc.), or other potentially contaminating microflora in the urine specimen.

5 By the term "target organism specific medium" is meant a medium capable of selectively sustaining the growth or ongoing viability of target microbial organisms. When the target organisms are uropathogenic bacteria, the "target organism specific medium" can be referred to as "uropathogen specific medium" or "UTI medium".

10 20 "Uropathogen specific medium" or "UTI medium" refer to a medium which allows only the growth of the primary urinary gram negative pathogens and allows for substantially less growth of any other bacteria of a biological matrix. In certain preferred embodiments, this term comprises media which contain one or more selecting compounds that are specific for inhibiting or preventing the growth of bacteria other than the primary gram negative urinary pathogens. In other preferred embodiments, it compromises media which contain one or more enzyme substrates which are preferably not hydrolyzed by enzymes from microorganisms other than the primary urinary gram negative pathogens to any substantial degree.

25 By the term "antimicrobial susceptibility interpretation medium" means a medium which allows the category of interpretation (e.g. susceptible, moderate susceptible, intermediate resistant, or resistant) of a detected target microbial organism relative to an antimicrobial agent or combinations thereof. These media are comprised of all components of the target organism specific media, such as the uropathogen specific medium, as well as a predetermined

amount of an antimicrobial agent. For example, when the target microbial organisms are uropathogenic bacteria, the antimicrobial susceptibility interpretation medium detects the susceptibility of the target organisms toward an antibiotic; the antimicrobial susceptibility interpretation medium can detect antimicrobial efficacy of one or more antibiotics toward the primary gram negative urinary pathogens.

By "signal generating substrate" is meant a molecule which can be metabolized by an enzyme or a group of enzymes of the microorganisms whose presence or growth ability are sought to be detected. These include but are not limited to hydrolyzable enzyme substrates and redox dyes. The enzymatic reaction typically involves hydrolyzing one or more covalent bonds of the substrate or transferring the reducing equivalents from a specific substrate to an acceptor. The substrates typically contain detectable moieties or can be converted to a detectable compound. Upon being metabolized by one or more microbial enzymes, the substrate generates a detectable moiety in the medium. In the preferred embodiments, the signal generating substrate is selected from the chromogenic or fluorogenic substrates of phosphatase, aminopeptidases (e.g., L-alanine aminopeptidase or L-leucine aminopeptidase), glycosidases, esterases, and sulfatases, as well as from the chromogenic or fluorogenic tetrazolium compounds (such as, sodium 3'-{1-[(phenylamino)-carbonyl]-3, 4-tetrazolium}bis(4-methoxy-6nitro) benzenesulfonic acid hydrate (XTT), 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride (INT), 5-cyano-2, 3-ditolyl tetrazolium chloride (CTC), 2, 3, 5-triphenyltetrazolium chloride (TTC), and resazurin, etc. This list is not meant

to exclude signal generating substrates which have yet to be discovered but may later be identified and include in this list by those of ordinary skill in the art. In alternative preferred embodiments, signal generating substrates employed in the viable organism control medium are 4-methylumbellifery-phosphate, 4-methylumbellifery- β -D-glucoside, and L-alanine-7-amido-4-methylcoumarin. In further preferred embodiments, the signal generating substrate used in the uropathogen specific medium and in the antimicrobial susceptibility interpretation medium is 4-methylumbelliferyl-phosphate.

By "signal generating moiety" is meant a molecule or substance which can be affiliated with a nutrient moiety or exists as a separate discrete entity. The signal generating moiety does not cause or produce a detectable signal when it is affiliated with (e.g., covalently bonded to) the nutrient moiety or before reduced and metabolized by the organisms. However, when an enzyme or a group of enzymes from viable target bacteria metabolize the signal generating substrate, a signal generating moiety is released or formed and causes or is capable of producing a detectable signal in the medium. In preferred embodiments, the detectable moieties are fluorogens which produce and emit fluorescence when properly excited by an external energy source, or chromogens which preferably produce a color change observable in the visible wavelength range (alternatively in the ultraviolet or infrared spectra). Examples of signal generating moieties include, but are not limited to: 4-methylumbelliferon, orthonitrophenyl, para-nitrophenyl, para-nitoanilide, 4-methoxy- β -naphthylamide, 7-amido-4-chloro-3-indoxyl, and formazan, etc. In a further preferred embodiment, the signal

65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
4410
4411
4412
4413
4414
4415
4416
4417
4418
4419
4420
4421
4422
4423
4424
4425
4426
4427
4428
4429
4430
4431
4432
4433
4434
4435
4436
4437
4438
4439
4440
4441
4442
4443
4444
4445
4446
4447
4448
4449
44410
44411
44412
44413
44414
44415
44416
44417
44418
44419
44420
44421
44422
44423
44424
44425
44426
44427
44428
44429
44430
44431
44432
44433
44434
44435
44436
44437
44438
44439
44440
44441
44442
44443
44444
44445
44446
44447
44448
44449
444410
444411
444412
444413
444414
444415
444416
444417
444418
444419
444420
444421
444422
444423
444424
444425
444426
444427
444428
444429
444430
444431
444432
444433
444434
444435
444436
444437
444438
444439
444440
444441
444442
444443
444444
444445
444446
444447
444448
444449
4444410
4444411
4444412
4444413
4444414
4444415
4444416
4444417
4444418
4444419
4444420
4444421
4444422
4444423
4444424
4444425
4444426
4444427
4444428
4444429
4444430
4444431
4444432
4444433
4444434
4444435
4444436
4444437
4444438
4444439
4444440
4444441
4444442
4444443
4444444
4444445
4444446
4444447
4444448
4444449
44444410
44444411
44444412
44444413
44444414
44444415
44444416
44444417
44444418
44444419
44444420
44444421
44444422
44444423
44444424
44444425
44444426
44444427
44444428
44444429
44444430
44444431
44444432
44444433
44444434
44444435
44444436
44444437
44444438
44444439
44444440
44444441
44444442
44444443
44444444
44444445
44444446
44444447
44444448
44444449
444444410
444444411
444444412
444444413
444444414
444444415
444444416
444444417
444444418
444444419
444444420
444444421
444444422
444444423
444444424
444444425
444444426
444444427
444444428
444444429
444444430
444444431
444444432
444444433
444444434
444444435
444444436
444444437
444444438
444444439
444444440
444444441
444444442
444444443
444444444
444444445
444444446
444444447
444444448
444444449
4444444410
4444444411
4444444412
4444444413
4444444414
4444444415
4444444416
4444444417
4444444418
4444444419
4444444420
4444444421
4444444422
4444444423
4444444424
4444444425
4444444426
4444444427
4444444428
4444444429
4444444430
4444444431
4444444432
4444444433
4444444434
4444444435
4444444436
4444444437
4444444438
4444444439
4444444440
4444444441
4444444442
4444444443
4444444444
4444444445
4444444446
4444444447
4444444448
4444444449
44444444410
44444444411
44444444412
44444444413
44444444414
44444444415
44444444416
44444444417
44444444418
44444444419
44444444420
44444444421
44444444422
44444444423
44444444424
44444444425
44444444426
44444444427
44444444428
44444444429
44444444430
44444444431
44444444432
44444444433
44444444434
44444444435
44444444436
44444444437
44444444438
44444444439
44444444440
44444444441
44444444442
44444444443
44444444444
44444444445
44444444446
44444444447
44444444448
44444444449
444444444410
444444444411
444444444412
444444444413
444444444414
444444444415
444444444416
444444444417
444444444418
444444444419
444444444420
444444444421
444444444422
444444444423
444444444424
444444444425
444444444426
444444444427
444444444428
444444444429
444444444430
444444444431
444444444432
444444444433
444444444434
444444444435
444444444436
444444444437
444444444438
444444444439
444444444440
444444444441
444444444442
444444444443
444444444444
444444444445
444444444446
444444444447
444444444448
444444444449
4444444444410
4444444444411
4444444444412
4444444444413
4444444444414
4444444444415
4444444444416
4444444444417
4444444444418
4444444444419
4444444444420
4444444444421
4444444444422
4444444444423
4444444444424
4444444444425
4444444444426
4444444444427
4444444444428
4444444444429
4444444444430
4444444444431
4444444444432
4444444444433
4444444444434
4444444444435
4444444444436
4444444444437
4444444444438
4444444444439
4444444444440
4444444444441
4444444444442
4444444444443
4444444444444
4444444444445
4444444444446
4444444444447
4444444444448
4444444444449
44444444444410
44444444444411
44444444444412
44444444444413
44444444444414
44444444444415
44444444444416
44444444444417
44444444444418
44444444444419
44444444444420
44444444444421
44444444444422
44444444444423
44444444444424
44444444444425
44444444444426
44444444444427
44444444444428
44444444444429
44444444444430
44444444444431
44444444444432
44444444444433
44444444444434
44444444444435
44444444444436
44444444444437
44444444444438
44444444444439
44444444444440
44444444444441
44444444444442
44444444444443
44444444444444
44444444444445
44444444444446
44444444444447
44444444444448
44444444444449
444444444444410
444444444444411
444444444444412
444444444444413
444444444444414
444444444444415
444444444444416
444444444444417
444444444444418
444444444444419
444444444444420
444444444444421
444444444444422
444444444444423
444444444444424
444444444444425
444444444444426
444444444444427
444444444444428
444444444444429
444444444444430
444444444444431
444444444444432
444444444444433
444444444444434
444444444444435
444444444444436
444444444444437
444444444444438
444444444444439
444444444444440
444444444444441
444444444444442
444444444444443
444444444444444
444444444444445
444444444444446
444444444444447
444444444444448
444444444444449
4444444444444410
4444444444444411
4444444444444412
4444444444444413
4444444444444414
4444444444444415
4444444444444416
4444444444444417
4444444444444418
4444444444444419
4444444444444420
4444444444444421
4444444444444422
4444444444444423
4444444444444424
4444444444444425
4444444444444426
4444444444444427
4444444444444428
4444444444444429
4444444444444430
4444444444444431
4444444444444432
4444444444444433
4444444444444434
4444444444444435
4444444444444436
4444444444444437
4444444444444438
4444444444444439
4444444444444440
4444444444444441
4444444444444442
4444444444444443
4444444444444444
4444444444444445
4444444444444446
4444444444444447
4444444444444448
4444444444444449
44444444444444410
44444444444444411
44444444444444412
44444444444444413
44444444444444414
44444444444444415
44444444444444416
44444444444444417
44444444444444418
44444444444444419
44444444444444420
44444444444444421
44444444444444422
44444444444444423
44444444444444424
44444444444444425
44444444444444426
44444444444444427
44444444444444428
44444444444444429
44444444444444430
44444444444444431
44444444444444432
44444444444444433
44444444444444434
44444444444444435
44444444444444436
44444444444444437
44444444444444438
44444444444444439
44444444444444440
44444444444444441
44444444444444442
44444444444444443
44444444444444444
44444444444444445
44444444444444446
44444444444444447
44444444444444448
44444444444444449
444444444444444410
444444444444444411
444444444444444412
444444444444444413
444444444444444414
444444444444444415
444444444444444416
444444444444444417
444444444444444418
444444444444444419
444444444444444420
444444444444444421
444444444444444422
444444444444444423
444444444444444424
444444444444444425
444444444444444426
444444444444444427
444444444444444428
444444444444444429
444444444444444430
444444444444444431
444444444444444432
444444444444444433
444444444444444434
444444444444444435
444444444444444436
444444444444444437
444444444444444438
444444444444444439
444444444444444440
444444444444444441
444444444444444442
444444444444444443
444444444444444444
444444444444444445
444444444444444446
444444444444444447
444444444444444448
444444444444444449
4444444444444444410
4444444444444444411
4444444444444444412
4444444444444444413
4444444444444444414
4444444444444444415
4444444444444444416
4444444444444444417
4444444444444444418
4444444444444444419
4444444444444444420
4444444444444444421
4444444444444444422
4444444444444444423
4444444444444444424
4444444444444444425
4444444444444444426
4444444444444444427
4444444444444444428
4444444444444444429
4444444444444444430
4444444444444444431
4444444444444444432
4444444444444444433
4444444444444444434
4444444444444444435
4444444444444444436
4444444444444444437
4444444444444444438
4444444444444444439
4444444444444444440
4444444444444444441
4444444444444444442
4444444444444444443
4444444444444444444
4444444444444444445
4444444444444444446
4444444444444444447
4444444444444444448
4444444444444444449
44444444444444444410
44444444444444444411
44444444444444444412
44444444444444444413
44444444444444444414
44444444444444444415
44444444444444444416
44444444444444444417
44444444444444444418
44444444444444444419
44444444444444444420
44444444444444444421
44444444444444444422
44444444444444444423<br

generating moiety produce an identical type of detectable fluorescent signal upon release from a nutrient moiety and cause a change of fluorescence in the medium.

By "detectable signal" is meant a characteristic change in a medium or sample that is observable or measurable by physical, chemical, or biological means known to those skilled in the art. Such a detectable signal may be assayed by chemical, visual, tactile, or olfactory means. For example, a change in emission or absorbency of: visible or invisible light or radio waves at a certain wavelength, electrical conductivity, emission of gas, turbidity or odor. A detectable signal may also be a change in physical state such as between solid, liquid and gas. The detectable signal may produce a chemical change, such as change in pH, which is measurable. Typically, a detectable signal is measured visually; in preferred embodiments, detectable signals comprise a change in fluorescent or color emission of the medium.

By the term "inoculation" is meant the time at which the test sample is mixed with media of the invention.

By "multi-compartmentalized device" is meant a device which comprises a number of individual compartments

By the term "effective amount of nutrients" is an amount of nutrients within the range which allows or promotes growth and reproduction of a target microorganism. That is, an amount which allows target microbes or other organisms to adapt to the media, continue metabolism, or synthesize the necessary constituents for reproduction and to subsequently reproduce.

By the term "effective amount of tested antibiotic" means an amount of an antibiotic within a range which is

sufficient to impede or eliminate continued growth or reproduction of microbial organisms.

5 The terms "vitamins", "amino acids", "trace elements" and "salts" are meant to include all molecules, compounds, and substances (whether organic or inorganic) classified in each category by those of ordinary skill in the art. The combination of these categories is intended to include any substance which may be necessary for, or conductive to, maintaining life of microorganisms.

10 By "test sample" or "biological sample" is meant a fraction, aliquot, droplet, portion, or volume of a biological sample such as urine, blood, saliva, cerebro-spinal fluid, fluid from a wound, fluid or material from a sight of infection, or, a chemical or an environmental sample. The sample can be taken from a patient source such as a human, dog, cat, or horse, or any other source. A test sample may be taken from a source using techniques known to one skilled in the art, including but not limited to, those described or referred to in "Manual of Clinical Microbiology" (6th ed.) 1995. edited by P.R. Murray, E.J. Baron, M.A. Pfaffer, F.C. Tenover, and R.H. Yolken.

15 In preferred embodiments, urine specimens may be obtained from cats or dogs suspected to have urinary tract infection by a number of means; including but are not limited to cystocentesis, catheterization, manual compression of bladder, and natural micturition.

Modes for Carrying Out the Invention

20 The present invention comprises a device and procedure to determine the antibiotic susceptibility (e.g., susceptible, moderately susceptible, intermediate resistant,

or resistant) of one or more antibiotics with respect to the urinary tract pathogens tested directly from a urine specimen. An aspect of the invention takes account of the interference caused by any contaminating microflora in the sample.

5

The present invention involves a microbiological method, compositions and apparatus for the direct detection and categorical interpretation of antibiotic susceptibility in relation to the majority of gram negative urinary tract pathogens directly from human or veterinary samples, such as urine or samples.

10

In preferred embodiments, a device in accordance with the invention comprises a series of wells, each well comprising an absorbent pad to which test media have been applied. Advantageously, the pad is capable of containing a liquid sample so that cross-contamination between wells is prevented, thus resulting in a reduced risk of erroneous results.

In alternative preferred embodiments, specific test media that have been applied to the well series of the test device include TVB medium, uropathogen specific medium, and a series of antimicrobial susceptibility interpretation media. The antimicrobial susceptibility interpretation media test series may be selected from, but are not limited to, the tests for the antimicrobial efficacy of amoxicillin, enrofloxacin, clavulanic acid/amoxicillin), cephalothin [cephalothin assay of often used to represent the efficacy of cephalothin, cephaprin, cephradine, cephalexin, cefaclor, and cefadroxil (NCCLS Antimicrobial Susceptibility Testing/SC3, January, 1996)], gentamicin, and chloramphenicol, etc. Preferably, the antimicrobial susceptibility interpretation

30

SSSD/50140, v01

-18-

media series for the primary urinary pathogens include tests for the efficacy of amoxicillin, enrofloxacin, clavulanic acid/amoxicillin, or cephalothin.

By the present invention, there is provided an improvement in the method of determining effective antibacterial therapy for human or veterinary urinary tract infections. Preferably, the present invention combines a series of microbial culture media which allows detecting the primary urinary pathogens and determining the antibacterial efficacy of selected antibiotics towards the detected urinary pathogens in a single step, in which a urine specimen obtained from a patient suspected of having an infection (i.e. UTI) is added to a series of microbiological growth media containing one or more hydrolyzable fluorogenic or colorogenic signal generating substrates; the series of growth media include TVB medium, uropathogen specific medium, and antimicrobial susceptibility interpretation media series. These test materials and processes can, in certain cases also be arranged to allow conventional microbiological culture to be continued so that the exact identity of a pathogen and the quantitative antimicrobial susceptibility information obtained later as a confirmation if desired.

EXAMPLES

Example 1

This example illustrates the preparation of the UTI media for the urinary tract infection assay device.

The medium is formulated according to techniques well known to those skilled in the art. The UTI medium contains

-19-

the following reagents in the concentration indicated in Table I.

Table I

	<u>g/L</u>
5	
HEPES Free Acid	6.864
HEPES Sodium Salt	5.292
Modified Yeast Nitrogen Base*	5.15
Yeast Extract	0.5
10	
Casein Peptone	10
Potassium Phosphate (monobasic)	0.1
Bile Salts #3	0.75
Vancomycin	0.01
Amphotericin B	0.0022
Clindamycin-HCl	0.005
4-MU Phosphate	0.05

* Yeast nitrogen base without salts (potassium phosphate, magnesium sulfate, sodium chloride, calcium chloride)

20 A total of 303 feline and canine urine specimens collected from the animals suspected of having urinary tract infection were tested with the uropathogen specific medium. A 50 μ l aliquot of the urine specimen was added to 10 ml of sterile saline solution (0.85% NaCl solution). A 100 μ l of the diluted urine specimens was added to the uropathogen specific medium in the urinary tract infection device; the device was then incubated at 35°C for 24 hours.

25 For comparison, a traditional microbiological culture and bacterial identification technique was used. A portion of 1 μ l urine specimen was streaked onto a blood agar plate; the plate was then incubated at 35°C for 24-48 hours. The

-20-

positive cultures (plates that showed microbial growth) was then subcultured and subjected to biochemical identification to obtain the identity of the isolated culture.

Results of the experiment are summarized in Table II.

These results indicated that the uropathogen specific medium has a positive predictive value of 94.8%, a negative predictive value of 99.2%, and an overall accuracy of 98.3%.

Table II
Uropathogen Specific Medium

Conventional culture and identification		Positive	Negative	Total
	Confirmed*	55	2	57
	Unconfirmed	3	243	246
	Total	58	245	303

* The isolated culture was confirmed to be the primary urinary pathogens; such as *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, and *Proteus mirabilis*.

Example 2

This example illustrates the preparation of the antimicrobial susceptibility interpretation medium with amoxicillin for the urinary tract infection assay device.

The medium is formulated according to techniques well known to those skilled in the art. The medium comprises UTI media with amoxicillin at a concentration of 8 mg/liter.

A total of 303 feline and canine urine specimens were collected from the animals suspected of having urinary tract infection were tested with the "AMO" medium. A 50 μ l aliquot of the urine specimen was added to 10 ml of sterile saline solution (0.85% NaCl solution). A 100 μ l of the diluted urine specimens were added to the "AMO" medium in the urinary

tract infection device; the device was then incubated at 35°C for 24 hours.

For comparison a traditional microbiological culture, bacterial identification technique, and antimicrobial susceptibility test were performed. A portion of 1 μ l urine specimen was streaked onto a blood agar plate; the plate was then incubated at 35°C for 24-48 hours. The positive culture (plates that showed microbial growth) was then subcultured and subjected to biochemical identification to obtain the identity of the isolated culture. The susceptibility of amoxicillin of the gram negative urinary pathogens (*Escherichia coli*, *Klebsiella spp*, *Enterobacter spp.*, and *Proteus spp.*) were performed by standard Kirby-Bauer antimicrobial susceptibility assay.

Results of the experiment are summarized in Table III. These results indicated that AMO medium is equivalent to the conventional antimicrobial susceptibility test in predicting the *Klebsiella spp*, *Enterobacter spp*, and *Proteus spp.*). The statistical agreement between these two methods were 96.6%.

Table III

AMO Medium

Amoxicillin susceptibility (Kirby-Bauer Assay)		Resistant	Susceptible	Total
	Resistant	21	1	22
	Susceptible	1	35	36
	Total	22	36	58

* One urine specimen exhibited pseudofluorescence which resulted in a false prediction by AMO medium

Example 3

5 This example illustrates the preparation of the antimicrobial susceptibility interpretation media with amoxicillin/clavulanic acid (AMC) (e.g., Clavamox®, Pfizer) for the urinary tract infection assay device.

10 The medium is formulated according to techniques well known to those skilled in the art. The medium comprises the UTI media with amoxicillin at a concentration of 12 mg/liter and clavulanic acid at a concentration of 6 mg/liter.

15 A total of 303 feline and canine urine specimens were collected from the animals suspected of having urinary tract infection were tested with the "AMC" medium. A 50 μ l aliquot of the urine specimen was added to 10 ml of sterile saline solution (0.85% NaCl solution). A 100 μ l of the diluted urine specimens was added to the "AMC" medium in the urinary tract infection device; the device was then incubated at 35°C for 24 hours.

20 For comparison a traditional microbiological culture, bacterial identification technique, and antimicrobial susceptibility test were performed. A portion of 1 μ l urine specimen was streaked onto a blood agar plate; the plate was then incubated at 35°C for 24-48 hours. The positive culture (plates that showed microbial growth) was then subcultured and subjected to biochemical identification to obtain the 25 identity of the isolated culture. The susceptibility of amoxicillin/clavulanic acid of the gram negative urinary pathogens (*Escherichia coli*, *Klebsiella spp*, *Enterobacter spp.*, and *Proteus spp.*) Were preformed by standard Kirby-Bauer antimicrobial susceptibility assay.

30 Results of the experiment are summarized in Table IV. These results indicated that AMC medium is equivalent to the

conventional antimicrobial susceptibility test in predicting the efficacy of amoxicillin/clavulanic acid in inhibiting the gram negative urinary pathogens (*Escherichia coli*, *Klebsiella spp.*, *Enterobacter spp.*, and *Proteus spp.*). The statistical agreement between these two methods were 91.4%.

5

10

15

20

25

30

Table IV
AMC Medium

Amoxicillin/ clavulanic acid suscep- tibility (Kirby-Bauer Assay)		Resistant	Susceptible	Total
	Resistant	9	2	11
	Susceptible	3*	44	47
	Total	12	46	58

* One urine specimen exhibited pseudofluorescence which resulted in a false prediction by AMC medium.

Example 4

This example illustrates the preparation of the antimicrobial susceptibility interpretation medium with enrofloxacin for the urinary tract infection assay device.

The medium is formulated according to techniques well known to those skilled in the art. The media comprises UTI media with enrofloxacin (ENR) at a concentration of 2.0 mg/liter.

A total of 303 feline and canine urine specimens were collected from the animals suspected of having urinary tract infection were tested with the "ENR" medium. A 50 μ l aliquot of the urine specimen was added to 10 ml of sterile saline solution (0.85% NaCl solution). A 100 μ l of the diluted urine specimens was added to the "ENR" medium in the urinary

tract infection device; the device was then incubated at 35°C for 24 hours.

For comparison a traditional microbiological culture, bacterial identification technique, and antimicrobial susceptibility test were performed. A portion of 1 μ l urine specimen was streaked onto a blood agar plate; the plate was then incubated at 35°C for 24-48 hours. The positive culture (plates that showed microbial growth) was then subcultured and subjected to biochemical identification to obtain the identity of the isolated culture. The susceptibility of enrofloxacin of the gram negative urinary pathogens (*Escherichia coli*, *Klebsiella spp*, *Enterobacter spp.*, and *Proteus spp.*) were performed by standard Kirby-Bauer antimicrobial susceptibility assay.

Results of the experiment are summarized in Table V. These results indicated that AMC medium is equivalent to the conventional antimicrobial susceptibility test in predicting the efficacy of enrofloxacin in inhibiting the gram negative urinary pathogens ('*Escherichia coli*, *Klebsiella spp*, *Enterobacter spp*, and *Proteus spp.*). The statistical agreement between these two methods were 94.8%.

Table V
ENR Medium

25 Suscepti- bility (Kirby- Bauer Assay)		Resistant	Susceptible	Total
	Resistant	5	1	6
	Susceptible	2	50	52
	Total	7	51	58

30 * One urine specimen exhibited pseudofluorescence which resulted in a false prediction by AMC medium.

Example 5

This example illustrated the preparation of the antimicrobial susceptibility interpretation medium with cephalothin (CR30) for the urinary assay device.

5 The medium is formulated according to techniques well known to those skilled in the art. The medium comprises the uropathogen specific medium with 32 mg/liter of cephalothin.

10 The representative primary gram negative urinary pathogens including *Escherichia coli* ATCC 25922, *Klebsiella pneumoniae*, *Enterobacter cloacae* ATCC 13047, and *Proteus mirabilis* were used to determine the antimicrobial efficacy of cephalothin in CR 30 medium in reaction to the standard Muller Hinton microdilution antimicrobial susceptibility ((NCCLS Antimicrobial Susceptibility Testing/SC3, January, 1996). Cephalothin was prepared in both standard Muller Hinton broth (MHB) and CR30 medium (CR30M) at the following concentrations: 128, 64, 32, 16, 8, 4, 2, and 0 mg/liter. Bacterial inocula used for each level of inoculation were 1-5 X 10⁴ cfu/100 µl. The assays were performed in microliter wells at 35°C for 18 hours.

20 Results of the experiment were summarized in Table VI. The bacteria are defined as "resistant" to cephalothin if the organism has an MIC of \geq 32 µg/ml, as "intermediate resistant" if the MIC is 16 µg/ml, and as "susceptible" if the MIC is 8 µg/ml as determined by the standard Muller Hinton broth (Manual of Clinical Microbiology, 6th ed. 1995; ASM Press). Results of this experiment indicated that *E. coli*, *K. pneumoniae*, and *P. mirabilis* were susceptible, and *E. cloacae* was resistant to cephalothin as determined by the standard Muller Hinton broth and an antimicrobial

susceptibility interpretation medium of this invention (CR30).

Table VI

		<u>E. coli</u>	<u>K. pneumoniae</u>	<u>E. cloacae</u>	<u>P. mirabilis</u>				
	<u>cephalothin</u>	<u>MHB</u>	<u>CR30M</u>	<u>MHB</u>	<u>CR30M</u>	<u>MHB</u>	<u>CR30M</u>	<u>MHB</u>	<u>CR30M</u>
5	0	+	+	+	+	+	+	+	+
	128	-	-	-	-	+	+	-	-
	64	-	-	-	-	+	+	-	-
	32	-	-	-	-	+	+	-	-
10	16	-	-	-	-	+	+	-	-
	8	+	+	-	-	+	+	-	-
	4	+	+	-	-	+	+	-	-
	2	+	+	-	+	+	+	-	-

Example 6

In a presently preferred embodiment, this invention comprises a device having a series of 5 test wells. Each well comprises a specific medium coupled with a fluorogenic enzyme substrate for the detection of target bacteria and their respective antibiotic resistance patterns. The wells produce a fluorescent signal when bacteria grow in them.

The wells were termed a total viable bacteria "TVB" well, a primary gram negative urinary tract infection organisms "UTI" well, and individual wells which contain an antimicrobial susceptibility media with an antibiotic amoxicillin "AMO", clavulanic acid/amoxicillin (Clavamox[®]) "AMC", or enrofloxacin (Baytril[®]) "ENR".

The total viable bacteria "TVB" well, when it fluoresces, indicates the presence of bacteria in the urine sample. The "UTI" well fluoresces when the common Gram-negative uropathogens (*E. coli*, *Klebsiella* or *Enterobacter*

spp., and *P. mirabilis*) are present in the urine sample. The antimicrobial susceptibility media wells, e.g., the "AMO", "AMC", and "ENR" wells contain reagent mixtures with an antibiotic, amoxicillin, clavulanic acid/amoxicillin (AMC) (e.g., Clavamox[®]), and enrofloxacin (Baytril[®]) in each respective well.

If there is growth in the UTI well, and one or more of the antibiotic wells which do not fluoresce after the incubation period, this indicates that the uropathogens are susceptible to the antibiotic in the respective test well, i.e., the bacteria have not grown in this well. Such a result suggests that the test antibiotic is a preferred choice for treating the urinary tract infection. When the bacteria are resistant to the antibiotic, the wells fluoresce, suggesting that the test antibiotic is not a preferred choice for treatment.

Table VII presents typical data for use of a preferred embodiment.

Table VII

<u>Result Patterns¹</u>							<u>Recommendation</u>
<u>TVB</u>	<u>UTI</u>	<u>AMO</u>	<u>AMC</u>	<u>ENR</u>	<u>Result Interpretation</u>		
5	-	-	-	-	-	No bacterial growth	
	+	-	-	-	-	No common Gram (-) uropathogens ³ detected	Confirmation by a reference laboratory ²
	+	+	-	-	-	1. Common Gram (-) uropathogens detected, 2. Uropathogens are susceptible to all three antibiotics	
	+	+	+	-	-	1. Common Gram (-) uropathogens detected, 2. Uropathogens are susceptible to Clavamox and enrofloxacin but are resistant to amoxicillin	
	+	+	-	+	-	1. Common Gram (-) uropathogens detected, 2. Uropathogens are susceptible to amoxicillin and enrofloxacin but are resistant to Clavamox	
	+	+	-	-	+	1. Common Gram (-) uropathogens detected, 2. Uropathogens are susceptible to amoxicillin and Clavamox but are resistant to enrofloxacin	
	+	+	+	+	-	1. Common Gram (-) uropathogens detected, 2. Uropathogens are susceptible to enrofloxacin but are resistant to amoxicillin and Clavamox	
	+	+	+	-	+	1. Common Gram (-) uropathogens detected, 2. Uropathogens are susceptible to Clavamox but are resistant to amoxicillin and enrofloxacin	
	+	+	-	+	+	1. Common Gram (-) uropathogens detected,	
	+	+	+	+	+	1. Common Gram (-) uropathogens	Confirmation by
1. If an atypical result pattern is obtained, it is recommended that the test device be sent to a reference laboratory for confirmation or a fresh urine sample be collected and analyzed by a reference laboratory.							
2. If these result patterns are obtained, it is also recommended that the test device be sent to a reference laboratory for standard microbial identification and antimicrobial susceptibility assays.							

In a preferred embodiment, one of the antimicrobial susceptibility media contained amoxicillin, the second contained a combination of amoxicillin and clavulanic acid, and the third contained enrofloxacin. By comparing the development of fluorescence between the wells, it was determined whether primary gram negative urinary pathogens were present and if so, their susceptibility to these antibiotics.

10

Example 7

Four urine samples were used to inoculate four different devices prepared as described in Example 6. A total of 303 feline and canine urine specimens were collected from the animals suspected of having urinary tract infection were tested with the "AMO" medium. A 50 μ l aliquot of the urine specimen was added to 10 ml of sterile saline solution (0.85% NaCl solution). A 100 μ l of the diluted urine specimens were added to the individual test wells in the urinary tract infection device; the device was then incubated at 35°C for 24 hours.

25

For each device, after an incubation period of 18 hours, the wells were examined for the development of fluorescence and conclusions about the presence of primary urinary pathogens and their susceptibility to the antimicrobial agents employed were drawn.

30

In Sample 1, both the TVB well and the UTI well developed fluorescence while none of the antimicrobial agent wells did. These results indicate that primary gram negative uropathogens are present which are susceptible to all three antimicrobial agents. In this case, for example, the health

care practitioner would preferably treat with the lowest cost alternative of the three medications.

Sample 2 exhibited fluorescence in the TVB well, the UTI well, the AMO, and AMC wells, but exhibited no fluorescence in the ENR well. These results indicate that primary gram negative uropathogens are present which are resistant to both amoxicillin and clavulanic acid/amoxicillin (e.g., Clavamox), but are susceptible to enrofloxacin. The health care practitioner therefore would know in only 18 hours that the only effective treatment option of the three antimicrobial agents assayed is enrofloxacin. Time and money need not be wasted in treating with an antibiotic to which the organisms are not susceptible. This example also illustrates the further benefit that the development of new resistant strains of microorganisms is discouraged by exposing the organisms only to the minimum number of antibiotics possible, and only to those to which they are susceptible.

Sample 3 exhibited fluorescence in the TVB well, the UTI well, and all three antimicrobial agent wells. These results indicate a primary gram negative uropathogen resistant to all three assayed antibiotics. In this case the health care practitioner learns in only 18 hours that another course of therapy must be sought and that the urine sample should be sent to a laboratory for further confirmatory testing to obtain a full spectrum of antimicrobial susceptibility of the isolated urinary pathogen against other antibiotics or to perform the quantitative antimicrobial susceptibility tests. No time is wasted treating with antibiotics to which the organism is resistant and the quick realization of the presence of a resistant strain enables the patient to be treated more immediately with an effective course of therapy.

Therefore, an additional benefit is that the further discomfort of the patient is minimized.

Finally, Sample 4 exhibited fluorescence only in the TVB well. Since the TVB well exhibits fluorescence the assay is valid. The fact that the UTI well did not exhibit fluorescence indicates that no primary gram negative uropathogens are present. This situation is consistent with a UTI caused by an organism which is not one of the primary uropathogens or a situation where there was contamination of the urinary sample. The health care practitioner could then obtain another urine sample or send the initial sample to a microbiology laboratory.

Example 8 (Ear Infection)

This example illustrates how a preferred embodiment of the invention is used to detect primary organisms associated with ear infections and to determine the susceptibility of such organisms to antimicrobial agents.

This embodiment comprises a total viable organisms "TVB" well and three primary ear infection organisms ("EIO") wells, one which contains a media capable of selectively sustaining the growth of gram positive primary ear infection organisms (e.g., *Staphylococcus spp.*) (EIO-S), another which contains a media capable of selectively sustaining the growth of primary gram negative ear infection organisms (e.g., *Pseudomonas spp.*) (EIO-P), and a third media capable of selectively sustaining the growth of *Candida* (CI), for the detection of yeast pathogens. There are also provided individual wells which contain antimicrobial susceptibility media. For the EIO-S and EIO-P associated wells, these antimicrobial agent wells contain the antibiotics gentamicin "GEN" and

enrofloxacin (Baytril[®]) "ENR." For the CI associated wells, the antimicrobial agent wells contain Tresderm "TRE" and Odemax "ODE." Therefore, a total of ten wells are provided in this embodiment.

Fluorescence in the total viable organisms "TVB" control well indicates the presence of nonspecific bacteria and fungi in the sample. The EIO-S and EIO-P wells fluoresce when the common gram negative or gram positive pathogens associated with ear infections for which the media select (*Staphylococcus spp.* or *Pseudomonas spp.*), respectively, are present in the sample. The "CI" well fluoresces when yeast are present in the sample. The "GEN," "ENR," "TRE," and "ODE" wells exhibit fluorescence when organisms resistant to that antimicrobial agent are present in the sample and do not fluoresce when susceptible organisms are present since no growth has occurred.

For example, a sample is presented into each well and incubated for 18-24 hours. Fluorescence is exhibited in the TVO well, the EIO-S well and the GEN well. No fluorescence is exhibited in the EIO-P well or CI well or any of their associated antimicrobial agent wells. These results indicate the presence of a pathogen from the gram positive *Staphylococcus spp.* group which is susceptible to enrofloxacin but resistant to gentamicin.

Example 9 (Skin Infection)

In another preferred embodiment, the invention is used to detect primary organisms associated with skin infections and to determine the susceptibility of the organisms to antimicrobial agents.

This embodiment comprises a total viable organisms "TVB" well, a primary skin infection organisms ("SIO") well, and individual wells which contain an antimicrobial susceptibility media with an antibiotic Cephalothin "CR30," enrofloxacin (Baytril[®]) "ENR," and keflex "KEF".

Fluorescence in the total viable organisms "TVB" well indicates the presence of bacteria in the sample from the skin. The "SIO" well fluoresces when common pathogens associated with skin infections are present in the sample. The "CR30," "ENR," and "KEF" wells contain antimicrobial susceptibility media with an antibiotic cephalothin, enrofloxacin (Baytril[®]), or keflex in their wells, respectively.

If there is growth in the TVB, or, TVB and SIO wells, other wells which do not fluoresce after the incubation period indicate that bacteria have not grown in that well and thus the pathogens present are susceptible to the antibiotic in that respective test well. Therefore, that antibiotic would be indicated as a potential course of treatment for the skin infection, whereas fluorescence in a well indicates that the pathogens are growing despite the presence of the antibiotic and that the organism is resistant to this antibiotic.

For example, each well is inoculated with an aliquot of a biological sample from a skin infection. After an incubation period of 18 hours, the wells are examined for the development of fluorescence. If fluorescence is found in the TVB well, the SIO well, and the CR30 well, this indicates that primary skin infection organisms are present which are resistant to cephalothin. Therefore, the health care practitioner is free to choose the lowest cost alternative

between enrofloxacin and keflex. Similarly, if fluorescence is found in the TVB well, the S10 well, and both the CR30 and KEF wells, this indicates primary gram negative skin infection organisms are present which are resistant to both cephalothin and keflex. The health care practitioner, therefore, learns in only 18 hours the resistance pattern of the infection-causing organisms and, in this case, knows that enrofloxacin will be an effective treatment option. Accordingly, no time is wasted treating with antibiotics to which the organism is resistant, and the rapid realization of the presence of a resistant strain enables the patient to be treated more immediately with an effective course of therapy. Thus, an additional benefit is that further discomfort of the patient is minimized.

Example 10 (General)

In other preferred embodiments the invention is used to determine the presence and susceptibility of organisms associated with many types of infections. These organisms can be any microorganisms including, but not limited to, bacteria, protists, and fungi. These embodiments comprise devices having a series of test wells. Each well comprises a specific medium coupled with a enzymatic means for achieving a sensible signal, such as a fluorogenic substrate, colorimetric substrate or a substrate that yields a change in a chemical parameter such as pH upon enzymatic change. The enzymatic means achieves detection of target organisms of the particular type of infection of interest and when such enzymatic means are included in an antimicrobial susceptibility media with the respective antibiotic resistance and susceptibility patterns generally associated

with that type of infection. Such wells produce a sensible signal (e.g., fluorescent, colorimetric or chemical) when organisms grow in them.

These embodiments contain wells termed a total viable organisms "TVB" well, a primary pathogenic organisms ("PPO") well, and individual wells which contain an antimicrobial susceptibility media with antimicrobial agents generally associated with the treatment of such infections and the resistance patterns particular to the subject organisms.

These antimicrobial agents can be chosen strictly for reasons associated with effective treatment, to investigate more economical treatment options, for reasons associated with avoiding the development of resistant strains of organisms, or for reasons chosen to serve any value.

Color change will be discussed as a preferred sensible signal. Color change in the total viable organisms "TVB" control well indicates the presence of microorganisms in the sample. The "PPO" well changes color when common pathogens associated with the particular type of infection are present in the sample. Selective media for the PPO will be prepared to detect the pathogens of the particular type of infection in accordance with techniques known in the art. The antimicrobial agent wells which change color indicate that target organisms are present in the sample which are resistant to the antimicrobial agent present in the well. Wells which do not change color indicate that the organisms are susceptible to the antimicrobial agent present in the well. Therefore, the health care practitioner can tailor the treatment of the infection with important and accurate information obtained in only 18 hours. The treatment of infections can focus almost immediately on antimicrobial

agents which are effective against the infecting organism. Patients obtain relief from the infection sooner because time need not be wasted treating with agents to which the organism are resistant. Moreover, the development of new resistant strains of infecting organisms is discouraged because infecting organisms are exposed to a minimum number of antimicrobial agents.

Therefore, the invention can acquire many embodiments and be broadly adapted to investigate the detection and treatment options for the particular types of organisms associate with various different infections.

Accordingly, the invention can comprise a device having any number of wells to enable the testing of a larger number of antibiotics and/or multiple samples. This would be particularly useful in achieving the goal of lowering the cost of treatment by testing not only the costly antibiotics and those with the greatest likelihood of success, but also cheaper drugs to which susceptibility may also be found. This also achieves the further goal of enabling health care practitioners to rely on newer, potent antibiotics only when absolutely necessary, thus discouraging the development of new resistant strains of bacteria to these new and valuable drugs.

25 Closing

It must be noted that as used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a formulation" includes mixtures of different formulations and reference to "the method of treatment" includes reference to equivalent

steps and methods known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar to equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. All publications and documents mentioned herein are fully incorporated by reference.

Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28 Q29 Q30 Q31 Q32 Q33 Q34 Q35 Q36 Q37 Q38 Q39 Q40 Q41 Q42 Q43 Q44 Q45 Q46 Q47 Q48 Q49 Q50 Q51 Q52 Q53 Q54 Q55 Q56 Q57 Q58 Q59 Q60 Q61 Q62 Q63 Q64 Q65 Q66 Q67 Q68 Q69 Q70 Q71 Q72 Q73 Q74 Q75 Q76 Q77 Q78 Q79 Q80 Q81 Q82 Q83 Q84 Q85 Q86 Q87 Q88 Q89 Q90 Q91 Q92 Q93 Q94 Q95 Q96 Q97 Q98 Q99 Q100

WHAT IS CLAIMED IS:

1. A multicompartiment assay device comprising:
 - at least one compartment comprising a viable organism control medium capable of sustaining growth of total microbial organisms;
 - at least one compartment comprising a medium capable of selectively sustaining growth of target microbial organisms; and,
 - at least one compartment comprising an antimicrobial susceptibility interpretation medium.
2. The device of claim 1 wherein the medium capable of sustaining growth of total microbial organisms comprises a total viable bacteria medium; wherein the target microbial organisms are bacteria; and the antimicrobial susceptibility interpretation medium comprises an antibiotic.
3. The device of claim 1 wherein the medium capable of sustaining growth of total microbial organisms comprises a total viable fungi medium; wherein the target microbial organisms are fungi; and, wherein the antimicrobial susceptibility interpretation medium comprises an antifungal agent.
4. The device of claim 1 wherein the medium capable of sustaining growth of total microbial organisms comprises a means for detection of total microbial organisms.

5. The device of claim 4 wherein the means for detection comprises an enzyme substrate comprising a detectable moiety capable of being released from the substrate by action of a microbial enzyme.

6. The device of claim 1 wherein the medium capable of sustaining growth of target microbial organisms comprises a means for detection of target microbial organisms.

7. The device of claim 6 wherein the means for detection of target microbial organisms comprises a signal generating substrate comprising a detectable moiety capable of being released from the substrate by action of a microbial enzyme.

8. The device of claim 1 wherein the antimicrobial susceptibility interpretation medium comprises a means for detection of microbial organisms which have grown or reproduced in the susceptibility interpretation medium.

9. The device of claim 8 wherein the means for detection comprises a signal generating substrate comprising a detectable moiety capable of being released from the substrate by action of a microbial enzyme.

10. The device of claim 1 wherein the medium capable of sustaining growth of total microbial organisms, the medium capable of sustaining growth of target microbial organisms, and, the antimicrobial susceptibility interpretation medium each comprise a means for producing an identical type of detectable signal.

11. The device of claim 1 wherein the at least one antimicrobial susceptibility interpretation medium comprises amoxicillin, clavulanic acid/amoxicillin, or, enrofloxacin.

12. A method of detecting the presence of target microbial microorganisms in a biological sample and of simultaneously determining the susceptibility of such microorganisms to antimicrobial agents, said method comprising steps of:

providing a multicompartiment assay device comprising: at least one compartment comprising a medium capable of sustaining growth of total microbial organisms; at least one compartment comprising a medium capable of sustaining growth of target microbial organisms; and, at least one compartment comprising an antimicrobial susceptibility interpretation medium;

placing a portion of the biological sample respectively in said at least one compartment comprising a medium capable of sustaining growth of total microbial organisms; said at least one compartment comprising a medium capable of sustaining growth of target microbial organisms; and, said at least one compartment comprising an antimicrobial susceptibility interpretation medium comprising an antimicrobial agent;

whereby growth of organisms in said at least one compartment comprising a medium capable of sustaining growth of total microbial organisms indicates the presence of bacteria in the sample; growth of organisms in said at least one compartment comprising a medium capable of sustaining growth of target microbial organisms indicates the presence of target microbial organisms in the sample, and growth of organisms in said at least one compartment comprising an antimicrobial susceptibility interpretation medium indicates that the organisms lack susceptibility to that antimicrobial agent.

13. The method of claim 12 which is a method of detecting target bacterial organisms or target fungal organisms.

14. The method of claim 12 wherein the biological fluid is urine, blood, saliva, cerebrospinal fluid, fluid from a wound, a chemical sample, or an environmental sample.

15. The method of claim 12 where the target microbial microorganisms are uropathogens.

16. The method of claim 15 where uropathogens comprise *Enterobacteriaceae*.

17. The method of claim 15 where uropathogens comprise *Escherichia coli*, *Klebsiella spp.*, *Enterobacter spp.*, *Proteus mirabilis* *Proteus vulgaris*, *Morganella morganii*, *Providencia rettgeri*, *Acinetobacter spp.*, *Staphylococcus aureus*, *Enterococcus faecalis*, or *Streptococci*.

18. The method of claim 12 where the step of providing a device comprising the at least one antimicrobial susceptibility interpretation medium provides antimicrobial susceptibility interpretation medium comprising amoxicillin, clavulanic acid/amoxicillin, or, enrofloxacin.

19. A multicompartiment assay device comprising:

a compartment comprising a medium capable of sustaining growth of total bacterial organisms;

a compartment comprising a medium capable of sustaining growth of target uropathogenic bacteria;

a compartment comprising an antimicrobial susceptibility interpretation medium comprising amoxicillin;

a compartment comprising an antimicrobial susceptibility interpretation medium comprising amoxicillin and clavulanic acid; and,

a compartment comprising an antimicrobial susceptibility interpretation medium comprising enrofloxacin.

METHOD AND APPARATUS FOR CONCURRENTLY DETECTING PATHOGENIC
ORGANISMS AND ANTIMICROBIAL SUSCEPTIBILITY

ABSTRACT OF THE DISCLOSURE

A multicompartiment assay device comprising at least one compartment comprising a viable organism control medium capable of sustaining growth of total microbial organisms; at least one compartment comprising a medium capable of selectively sustaining growth of target microbial organisms; and, at least one compartment comprising an antimicrobial susceptibility interpretation medium. Also, a method of detecting the presence of target microbial microorganisms in a biological sample and of simultaneously determining the susceptibility of such microorganisms to antimicrobial agents by use of such a device.

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHOD AND APPARATUS FOR CONCURRENTLY DETECTING PATHOGENIC ORGANISMS AND ANTIMICROBIAL SUSCEPTIBILITY, the specification of which

X is attached hereto.
was filed on _____ as Application Serial No. _____ and was amended
on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Timothy J. Lithgow, Registration No. 36,856.

[X] Kindly recognize as associate attorney:

Roland N. Smoot, Reg. No. 18,718; Conrad R. Solum, Jr. Reg. No. 20,467; James W. Geriak, Reg. No. 20,233; Robert M. Taylor, Jr., Reg. No. 19,848; Samuel B. Stone, Reg. No. 19,297; Douglas E. Olson, Reg. No. 22,798; Robert E. Lyon, Reg. No. 24,171; Robert C. Weiss, Reg. No. 24,939; Richard E. Lyon, Jr., Reg. No. 26,300; John D. McConaghay, Reg. No. 26,773; William C. Steffin, Reg. No. 26,811; Coe A. Bloomberg, Reg. No. 26,605; J. Donald

McCarthy, Reg. No. 25,119; John M. Benassi, Reg. No. 27,483; James H. Shalek, Reg. No. 29,749; Allan W. Jansen, Reg. No. 29,035; Robert W. Dickerson, Reg. No. 29,914; Roy L. Anderson, Reg. No. 30,240; David B. Murphy, Reg. No. 31,125; James C. Brooks, Reg. No. 29,898; Jeffrey M. Olson, Reg. No. 30,790; Steven D. Hemminger, Reg. No. 30,755; Jerrold B. Reilly, Reg. No. 32,293; Paul H. Meier, Reg. No. 32,274; John A. Rafter, Jr., Reg. No. 31,653; Kenneth H. Ohriner, Reg. No. 31,646; Mary S. Consalvi, Reg. No. 32,212; Lois M. Kwasigroch, Reg. No. 35,579; Lawrence R. LaPorte, Reg. No. 38,948; Robert C. Laurenson, Reg. No. 34,206; Bradford J. Duft, Reg. No. 32,219; Suzanne L. Biggs, Reg. No. 30,158; Richard J. Warburg, Reg. No. 32,327; Jessica R. Wolff, Reg. No. 37,261; Sheldon O. Heber, Reg. No. 38,179; Jeffrey W. Guise, Reg. No. 34,613; F.T. Alexandra Mahaney, Reg. No. 37,668; Charles S. Berkman, Reg. No. 38,077; Anthony C. Chen, Reg. No. 38,673; Edward M. Jordan, Reg. No. 40,666; John C. Kappos, Reg. No. 37,861; William J. Kolegraff, Reg. No. 41,125; Stephen S. Korniczky, Reg. No. 34,853; Jonathan T. Losk, Reg. No. 39,755; Theodore S. Maceiko, Reg. No. 35,593; Hope E. Melville, Reg. No. 34,874; Jeffrey A. Miller, Reg. No. 35,874; Kurt T. Mulville, Reg. No. 37,194; Clarke W. Neumann, Reg. No. 39,789; Vicki Norton, Reg. No. 40,745; Kenneth S. Roberts, Reg. No. 38,283; Thomas R. Rouse, Reg. No. 40,793; James K. Sakaguchi, Reg. No. 41,285; James K. Sakaguchi, Reg. No. 41,285; Carol A. Schneider, Reg. No. 34,923; Gary H. Silverstein, Reg. No. 39,372; Sheryl R. Silverstein, Reg. No. 40,812; Brent D. Sokol, Reg. No. 38,621; Jeffrey D. Tekanic, Reg. No. 36,031; Christopher A. Vanderlaan, Reg. No. 37,747; David E. Wang, Reg. No. 38,358; Lisa Ward Karmelich, Reg. No. 41,421; Michael J. Wise, Reg. No. 34,047; Wesley Ames, Reg. No. 40,893; Charles Balgenorth, Reg. No. 37,586; Thomas J. Brindisi, Reg. No. 40,348; James P. Brogan, Reg. No. 35,833; David T. Burse, Reg. No. 37,104; Bruce G. Chapman, Reg. No. 33,846; Farshad Farjami, Reg. No. 41,014; Charles C. Fowler, Reg. No. 39,675; and Corrine M. Freeman, Reg. No. 37,625.

Address all telephone calls to Timothy J. Lithgow at telephone no. (619) 552-8400

Address all correspondence to Timothy J. Lithgow, Lyon & Lyon, 633 West Fifth Street, Suite 4700, Los Angeles, CA 90071-2066

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issuing thereon.

Full name of first inventor Chun-Ming Chen _____
Inventor's signature _____ Date _____
Residence 17 Slocum Drive, Falmouth, ME 04105
Citizenship Taiwan
Post Office Address _____

Full name of first inventor Charles R. Carpenter _____
Inventor's signature _____ Date _____
Residence 175 Holmes Road, Scarborough, Maine 04074
Citizenship United States of America
Post Office Address _____

Full name of second inventor Haoyi Gu _____
Inventor's signature _____ Date _____
Residence 22 Waverly Street, Portland, ME 04103
Citizenship China
Post Office Address 22 Waverly Street, Portland, ME 04103

Full name of second inventor Ali Naqui _____
Inventor's signature _____ Date _____
Residence 2 Pinehurst Lane, Falmouth, Maine 04105
Citizenship United States of America
Post Office Address _____